Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clinical Research Agendas Get A Boost From Social Media

This article was originally published in The Pink Sheet Daily

Executive Summary

Women who survived a rare cardiovascular event banded together online and approached Mayo Clinic investigators with a research agenda, and AstraZeneca is using a YouTube video to find Internet-savvy patients who might be reluctant to reach out about their condition.

You may also be interested in...



Rare Disease R&D: FDA To Use NIH Registry For Natural History Studies

NIH plans to select two dozen groups to participate in a Global Rare Disease Patient Registry pilot project, which FDA hopes will lead to a better understanding of the conditions and speed drug development.

FDA Proposals For Studying Internet Promotions Raise Concerns

FDA should not delay draft guidance on Internet and social media promotional activities while it studies how consumer understanding of a drug’s safety and efficacy is affected by the techniques used to present information on branded websites, according to comments on the proposed studies.

Myeloma Foundation Uses Patient Connections To Help Speed Drug Trials

Bolstered by a huge patient database, the Multiple Myeloma Research Consortium is helping to speed trials of new therapies, including some of the most talked about investigational drugs in the disease space, like carfilzomib and pomalidomide.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS072792

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel